
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated a robust growth trajectory, with a year-over-year increase of 57% in the central nervous system (CNS) segment, supported by a higher-than-expected mix of new patient starts (NPS) in the pharmacy channel. The management's decision to raise 2025 and 2026 revenue estimates to $97.5 million and $136 million, respectively, reflects strong momentum in new prescriptions and the successful expansion of sales territories. Additionally, the company is well-positioned for sustained growth, projecting a compound annual growth rate (CAGR) of 30-40% from 2024 to 2028, further bolstered by a solid quarter of financial performance and an increase in revenue guidance.
Bears say
Beta Bionics faces significant risks that could adversely affect its financial performance, particularly following the disappointing launch of the iLet Bionic Pancreas amid competitive pressures, which may hinder market share and revenue growth. Delays in clinical development timelines could further obstruct the company's ability to penetrate pharmacy channels effectively and may necessitate additional capital investments, potentially leading to shareholder dilution. Furthermore, pending Medicare payment model proposals and regulatory uncertainties threaten to create additional headwinds, contributing to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares